✦ LIBER ✦

Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable

✍ Scribed by Julie Gralow; Hope Rugo; William Gradishar; Joyce A. O'Shaughnessy; Mohammed Jahanzeb; Edith Perez; Debu Tripathy

Book ID: 115075797
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 86 KB
Volume: 8
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2008.n.046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management of cancer treatment-induced b

Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club

✍ J. J. Body; P. Bergmann; S. Boonen; Y. Boutsen; J. P. Devogelaer; S. Goemaere; J 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 226 KB

A Phase II trial of the combination of v

A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines

✍ George Orphanos; Athanasios Alexopoulos; Savvoula Malliou; George Ioannidis; Ale 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 312 KB

A pilot study to evaluate the impact of

A pilot study to evaluate the impact of involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan

✍ E.T. Choy; A. Chiu; P. Butow; J. Young; A. Spillane 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 170 KB

A multicenter phase II study of TSU-68,

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane

✍ Suzuki, Yasuhiro; Saeki, Toshiaki; Aogi, Kenjiro; Toi, Masakazu; Fujii, Hirofumi 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 259 KB

Comparative clinical efficacy and safety

Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain

✍ Neil A. Hagen; Najib Babul 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 2 views

Fredphone, each given every 12 hours for 7 days. Pain intensity, nausea, and sedation erick, Pickering, Ontario, Canada. were assessed by patients four times daily, and breakthrough analgesia was recorded. ## RESULTS. Thirty-one patients completed the study (18 women, 13 men; mean age, 56 { 3 ye

First-in-man application of a novel ther

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

✍ Neil L Berinstein, Mohan Karkada, Michael A Morse, John J Nemunaitis, Gurkamal C 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 269 KB